Decei Pharma and Bristol-Myers Squibb will jointly promote the clinical development of ATG-017 and Odivo

ATG-017 is an oral small molecule ERK1/2 inhibitor; Odivo® is a PD-1 checkpoint inhibitor.

Shanghai and Hong Kong, December 13, 2021/PRNewswire/ - Deqi Pharmaceutical Co.

Dr.

ATG-017 is a selective oral inhibitor that acts on extracellular signal-regulated kinase 1 and 2 (ERK1/2)

Dr.

ATG-017 is currently being evaluated in an open, multicenter, phase 1/2 dose exploratory trial called ERASER for the treatment of patients with mutations in the RAS-MAPK pathway

According to the agreement, Deqi Pharmaceuticals will be responsible for the development of the clinical trial and provide financial support

About ATG-017

ATG-017 is a potent and selective small molecule inhibitor that acts on extracellular signal-regulated kinase 1 and 2 (ERK1/2)

Deqi Pharmaceuticals announced relevant preclinical research data at the 2021 Society of Tumor Immunotherapy (SITC) Annual Meeting held recently

About Deqi Pharmaceutical

Deqi Pharmaceutical Co.

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article

Source: Deqi Pharmaceutical Co.